Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!
you are here: HomeNewsTrends

Japan's donor agency JICA to provide Rs 3,500 crore loan to India to boost COVID-19 fight

The objective of the project is to strengthen public healthcare system, by extending budget support to the Indian government in implementing emergency response programmes for the health sector as countermeasures against the COVID-19, the Japan International Cooperation Agency (JICA) said in a statement.

August 31, 2020 / 10:21 PM IST
Representative Image

Representative Image


Japan's donor agency JICA on Monday signed an agreement with the Indian government under which it will provide about Rs 3,500 crore in loan to boost the fight against the COVID-19 pandemic in India. This loan will be disbursed to the Government of India for supporting anticipated financing requirement for the implementation of "Prime Minister Atmanirbhar Swasth Bharat Yojana (PM-ASBY)" governed by the Ministry of Health and Family Welfare as the Atmanirbhar Bharat Package for the health sector.

The objective of the project is to strengthen public healthcare system, by extending budget support to the Indian government in implementing emergency response programmes for the health sector as countermeasures against the COVID-19, the Japan International Cooperation Agency (JICA) said in a statement. This will contribute to promoting the social and economic stabilization and development efforts of India, it said.

JICA signed with the Indian government to provide an Official Development Assistance (ODA) loan of 50 billion Japanese Yen (approximately INR 3,500 Crore) as the "COVID-19 Crisis Response Emergency Support Loan". The ODA loan agreement was signed between C S Mohapatra, Additional Secretary, Department of Economic Affairs, Ministry of Finance and Katsuo Matsumoto, Chief Representative, JICA India.

Speaking on the occasion, Matsumoto said, "With the outbreak of novel coronavirus disease (COVID-19), we commend Government of India's swift response to prevent the spread of COVID-19 and support their vision to build a robust healthcare system under PM-ASBY". "Our policy-based lending will be utilized for strengthening the public healthcare system and JICA will closely monitor the critical activities such as implementation of medical teleconsultation services, strengthening national health information reporting platform, and development of infectious disease hospitals," he said.

He said JICA expects that PM-ASBY will improve accessibility, affordability, availability, awareness and quality of healthcare services in the whole nation. This is the first large scale Japanese ODA to support the Indian government's fight against COVID-19 and we will continue supporting it with all possible measures we can provide, Matsumoto said.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"Based on a national COVID-19 containment strategy, the government of India's response has been pre-emptive, proactive and characterized by a 'whole government' approach with the highest level of political commitment," the statement said. Through PM-ASBY, the Ministry of Health and Family Welfare will implement measures to strengthen the public healthcare system, expand and strengthen surveillance capacities, research and national digital health mission, it said.

Along with the financial support, JICA is considering the provision of technical assistance for monitoring the activities under the PM-ASBY and share Japanese knowledge for better implementation, the statement said. In India, JICA has cumulatively extended ODA loans of 42.5 billion Japanese Yen (approximately Rs 2,833 crore) for the health-care sector, since 1995/96. JICA has health projects in Tamil Nadu and Odisha amongst other states in India.

JICA aims to contribute to the promotion of international cooperation, as a sole Japanese governmental agency in charge of ODA implementation.

PTI
first published: Aug 31, 2020 10:21 pm

stay updated

Get Daily News on your Browser
Sections